Hepatitis C virus genotypes, HLA-DRB alleles and their response to interferon-α and ribavirin in patients with chronic hepatitis C

被引:0
|
作者
Jian Jiao and Jiang-Bin Wang Changchun
机构
关键词
chronic hepatitis C; genotype; HLA; interferon-α; ribavirin;
D O I
暂无
中图分类号
R512.63 [];
学科分类号
100401 ;
摘要
BACKGROUND: Hepatitis C virus (HCV) is a worldwide common disease. Some predictive factors influencing the response to interferon alpha (IFN-α) therapy have been identified, but the conclusions differ in various counties and areas. The aim of this study was to study the associa- tions between HCV genotypes, HLA-DRB alleles and their response to IFN-α and ribavirin in Chinese patients with chronic hepatitis C in Northeast China. METHODS: HCV genotypes of 113 patients with HCV were investigated. Gene chips were used to analyze the fre- quency of HLA-DRB in 25 of these patients and their re- sponse to IFN-α and ribavirin. The associations of HCV genotypes, HLA-DRB alleles and their response to IFN-α and ribavirin were also studied. RESULTS: The response rates differed in several types of HCV, with HCV 2b being the highest (57.78% ), HCV 1a and 2a lower (46.15% and 47.62% ) and HCV 1b the low- est (11.76% ). The response rates to IFN-α and ribavirin in patients with DRB1 07 were higher than those with DRB1 04. Sex, HCV type and HLA-DRB were all related to the response. Most female patients with HCV 2b and HLA- DRB1 07 presented complete response, whereas male pa- tients with HCV 1b and HLA-DRB1 04 usually demon- strated no response. DRB1 07 allele and HCV 2b were the factors closely related to the response. CONCLUSIONS: The response rate of HCV 1b may be the lowest even IFN-α and ribavirin are combined in treat- ment. Not only virus but also the host plays an important role in anti-virus therapy. Thus, it is necessary to adjust the host’s immune status to accelerate the clearance of HCV.
引用
收藏
页码:80 / 83
页数:4
相关论文
共 50 条
  • [1] Treatment with ribavirin and interferon-α reduces interferon-γ expression in patients with chronic hepatitis C
    Bergamini, A
    Bolacchi, F
    Cepparulo, M
    Demin, F
    Uccella, I
    Bongiovanni, B
    Ombres, D
    Angelico, F
    Liuti, A
    Hurtova, M
    Francioso, S
    Carvelli, C
    Cerasari, G
    Angelico, M
    Rocchi, G
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2001, 123 (03) : 459 - 464
  • [2] The effect of HLA alleles on response to interferon therapy in patients with chronic hepatitis C
    Kikuchi, I
    Ueda, A
    Mihara, K
    Miyanaga, O
    Machidori, H
    Ishikawa, E
    Tamura, K
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1998, 10 (10) : 859 - 863
  • [3] Ribavirin enhances interferon-γ levels in patients with chronic hepatitis C treated with interferon-α
    Fang, SH
    Lai, MY
    Hwang, LH
    Yang, PM
    Chen, PJ
    Chiang, BL
    Chen, DS
    JOURNAL OF BIOMEDICAL SCIENCE, 2001, 8 (06) : 484 - 491
  • [4] Combination therapy with interferon-α and ribavirin in patients with dual hepatitis B and hepatitis C virus infection
    Hung, CH
    Lee, CM
    Lu, SN
    Wang, JH
    Tung, HD
    Chen, CH
    Changchien, CS
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 20 (05) : 727 - 732
  • [5] Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients
    Frei, Pascal
    Leucht, Anna-Kathrin
    Held, Ulrike
    Kofmehl, Reto
    Manser, Christine N.
    Schmitt, Johannes
    Mertens, Joachim
    Rau, Monika
    Baur, Katharina
    Gerlach, Tilman
    Negro, Francesco
    Heim, Markus
    Moradpour, Darius
    Cerny, Andreas
    Dufour, Jean-Francois
    Muellhaupt, Beat
    Geier, Andreas
    LIVER INTERNATIONAL, 2014, 34 (04) : 551 - 557
  • [6] Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-α therapy
    Böcher, WO
    Schuchmann, M
    Link, R
    Hillenbrand, H
    Rahman, F
    Sprinzl, M
    Mudter, J
    Löhr, HF
    Galle, PR
    LIVER INTERNATIONAL, 2006, 26 (03) : 319 - 325
  • [7] Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients
    Dai, Chia-Yen
    Chuang, Wan-Long
    Hsieh, Ming-Yen
    Huang, Jee-Fu
    Lin, Ya-Yun
    Chu, Pei-Yu
    Hou, Nai-Jen
    Lin, Zu-Yau
    Chen, Shinn-Cherng
    Hsieh, Ming-Yuh
    Wang, Liang-Yen
    Yu, Ming-Lung
    ANTIVIRAL RESEARCH, 2010, 85 (02) : 396 - 402
  • [8] Treatment of interferon-α for chronic hepatitis C
    Moriyama, Mitsuhiko
    Arakawa, Yasuyuki
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (09) : 1163 - 1179
  • [9] Hepatitis C virus genotypes in elderly patients with chronic hepatitis C
    Carra, R
    Elia, G
    Santangelo, N
    Trovato, BA
    Rosso, D
    Giunta, E
    Siciliano, R
    ARCHIVES OF GERONTOLOGY AND GERIATRICS, 1996, : 287 - 290
  • [10] Th1 response during ribavirin and interferon-α combination therapy in chronic hepatitis C
    Kobayashi, K
    Ueno, Y
    Kobayashi, Y
    Akahaned, T
    Satoh, S
    Kikuchi, K
    Okamoto, H
    Ishii, M
    Shimosegawa, T
    HEPATOLOGY RESEARCH, 2006, 34 (02) : 104 - 110